JP2022513405A5 - - Google Patents

Info

Publication number
JP2022513405A5
JP2022513405A5 JP2021548551A JP2021548551A JP2022513405A5 JP 2022513405 A5 JP2022513405 A5 JP 2022513405A5 JP 2021548551 A JP2021548551 A JP 2021548551A JP 2021548551 A JP2021548551 A JP 2021548551A JP 2022513405 A5 JP2022513405 A5 JP 2022513405A5
Authority
JP
Japan
Application number
JP2021548551A
Other languages
Japanese (ja)
Other versions
JPWO2020092533A5 (https=
JP2022513405A (ja
JP7630435B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/058824 external-priority patent/WO2020092533A2/en
Publication of JP2022513405A publication Critical patent/JP2022513405A/ja
Publication of JPWO2020092533A5 publication Critical patent/JPWO2020092533A5/ja
Publication of JP2022513405A5 publication Critical patent/JP2022513405A5/ja
Priority to JP2025015899A priority Critical patent/JP2025072466A/ja
Application granted granted Critical
Publication of JP7630435B2 publication Critical patent/JP7630435B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021548551A 2018-10-30 2019-10-30 抗cd123免疫複合体を用いた治療法 Active JP7630435B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025015899A JP2025072466A (ja) 2018-10-30 2025-02-03 抗cd123免疫複合体を用いた治療法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862752832P 2018-10-30 2018-10-30
US62/752,832 2018-10-30
US201962860565P 2019-06-12 2019-06-12
US62/860,565 2019-06-12
US201962881137P 2019-07-31 2019-07-31
US62/881,137 2019-07-31
PCT/US2019/058824 WO2020092533A2 (en) 2018-10-30 2019-10-30 Methods of treatment using anti-cd123 immunoconjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025015899A Division JP2025072466A (ja) 2018-10-30 2025-02-03 抗cd123免疫複合体を用いた治療法

Publications (4)

Publication Number Publication Date
JP2022513405A JP2022513405A (ja) 2022-02-07
JPWO2020092533A5 JPWO2020092533A5 (https=) 2022-11-08
JP2022513405A5 true JP2022513405A5 (https=) 2022-11-08
JP7630435B2 JP7630435B2 (ja) 2025-02-17

Family

ID=70464182

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021548551A Active JP7630435B2 (ja) 2018-10-30 2019-10-30 抗cd123免疫複合体を用いた治療法
JP2025015899A Pending JP2025072466A (ja) 2018-10-30 2025-02-03 抗cd123免疫複合体を用いた治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025015899A Pending JP2025072466A (ja) 2018-10-30 2025-02-03 抗cd123免疫複合体を用いた治療法

Country Status (12)

Country Link
US (2) US20200157228A1 (https=)
EP (1) EP3873524B8 (https=)
JP (2) JP7630435B2 (https=)
KR (1) KR20210087951A (https=)
CN (2) CN118557748A (https=)
AU (1) AU2019370291B2 (https=)
CA (1) CA3117493A1 (https=)
IL (1) IL282685A (https=)
MA (1) MA54088A (https=)
SG (1) SG11202103999VA (https=)
TW (1) TWI870363B (https=)
WO (1) WO2020092533A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3137454A1 (en) 2019-04-29 2020-11-05 Immunogen, Inc. Therapeutic combinations comprising anti-cd123 immunoconjugates
US20250345449A1 (en) * 2024-05-10 2025-11-13 Immunogen, Inc. Anti-cd123 immunoconjugates for the treatment of blastic plasmacytoid cell neoplasm

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
WO2008127735A1 (en) * 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
JP2011509675A (ja) 2008-01-18 2011-03-31 メディミューン,エルエルシー 部位特異的コンジュゲーションのためのシステイン操作抗体
AU2010270979B2 (en) 2009-06-22 2015-04-23 Medimmune, Llc Engineered Fc regions for site-specific conjugation
SI2900277T1 (sl) * 2012-12-13 2022-05-31 Immunomedics, Inc. Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost
CA2911499A1 (en) * 2013-05-14 2014-11-20 Immunogen, Inc. Anti-folr1 immunoconjugate dosing regimens
CN115124573A (zh) * 2013-09-02 2022-09-30 杭州多禧生物科技有限公司 应用于细胞结合分子-药物共轭体的新型细胞毒性分子
TW201709932A (zh) * 2015-06-12 2017-03-16 西雅圖遺傳學公司 Cd123抗體及其共軛物
ES2887273T3 (es) 2015-06-29 2021-12-22 Immunogen Inc Anticuerpos anti-CD123 y conjugados y derivados de los mismos
EP3769787A1 (en) 2015-06-29 2021-01-27 ImmunoGen, Inc. Conjugates of cysteine engineered antibodies
TWI845890B (zh) * 2016-11-23 2024-06-21 美商伊繆諾金公司 苯二氮平衍生物之選擇性磺化
TW202021618A (zh) * 2018-08-17 2020-06-16 美商23與我有限公司 抗il1rap抗體及其使用方法

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)